Saurabh Saha, Centessa CEO (BIO19)

One of 2021's star biotech play­ers flags an­oth­er big set­back for the pipeline

Two months af­ter scut­tling their lead drug, Centes­sa’s ex­ec­u­tive team is back with the lat­est in a se­ries of set­backs that have tanked its stock and blown holes in its strate­gic line­up of biotech subs.

The com­pa­ny re­port­ed in its Q2 post to­day that it has de­cid­ed to scrap ZF874 af­ter a pa­tient demon­strat­ed el­e­vat­ed liv­er en­zymes — a clas­sic red safe­ty flag — in a Phase I study for al­pha-1-an­tit­rypsin (A1AT).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.